BioSpace News Archive

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting.

Constellation Pharmaceuticals, Inc. announced that the Company will present updates of clinical data from the MANIFEST clinical trial of CPI-0610 in oral and poster presentations at the American Society of Hematology (ASH) annual meeting on December 9.

Glassbeam, Inc. announced that it has expanded its strategic reseller relationship with Agiliti Imaging, a division of Agiliti, Inc., more than doubling its current installed base in the Southern California region.

Ionis scientists, including CEO Stanley Crooke, M.D., Ph.D., recognized with prestigious Paper of the Year Award for their work on advancing core antisense research

Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure for Advanced Glaucoma

In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that James Sapirstein has been appointed to serve as the Company’s President and Chief Executive Officer following the resignation of Thijs Spoor from the same positions

Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license

BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be exhibiting at the 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy on October 11-12, 2019 at Hyatt at the Bellevue in Philadelphia, PA.

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the Company would be presenting three posters on Elayta™ (CT1812), Cognition’s lead experimental medicine, during the 2019 Society for Neuroscience annual conference